What is Arcutis Biotherapeutics, Inc.'s earnings per share (EPS)?

Arcutis Biotherapeutics, Inc. (ARQT) reported diluted earnings per share of $-0.13 for fiscal year 2025. This represents a 88.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Arcutis Biotherapeutics, Inc. Financials

ARQT

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Arcutis Biotherapeutics, Inc. (ARQT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ARQT FY2025 2026-05-06

A high-gross-margin revenue ramp nearly erased losses, but working-capital absorption kept cash generation just below break-even.

FY2025's near break-even cash burn came alongside steady R&D, not a retreat in investment: research spending stayed near $77.1M while revenue climbed to $376.1M. The remaining cash drain looks mostly like working-capital absorption, because accounts receivable doubled to $146.2M as operating cash flow improved to just -$5.6M.

With gross margin still around 90.2%, the company kept its core economics intact as it scaled, so the operating loss narrowed to -$12.2M without needing a richer gross-profit mix. That pattern points to fixed-cost absorption rather than a one-off cost cut: selling and administrative expense rose, but far more slowly than revenue.

Liquidity looks better than the cash line alone because the current ratio remained 3.2x even with cash down to $42.9M. But more of those current assets are now tied up in receivables instead of cash, and long-term debt of $108.0M means day-to-day flexibility depends more on collections than on a large cash cushion.

Financial Health Signals

Financial Health Score 46/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Arcutis Biotherapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Arcutis Biotherapeutics, Inc. has an operating margin of -3.3%, meaning the company retains $-3 of operating profit per $100 of revenue. This below-average margin results in a low score of 12/100, suggesting thin profitability after operating expenses. This is up from -65.3% the prior year.

Growth

Arcutis Biotherapeutics, Inc.'s revenue surged 91.3% year-over-year to $376.1M, reflecting rapid business expansion. This strong growth earns a score of 98/100.

Leverage

Arcutis Biotherapeutics, Inc. has a moderate D/E ratio of 0.57. This balance of debt and equity financing earns a leverage score of 57/100.

Liquidity

With a current ratio of 3.17, Arcutis Biotherapeutics, Inc. holds $3.17 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 79/100.

Cash Flow

While Arcutis Biotherapeutics, Inc. generated -$5.6M in operating cash flow, capex of $686K consumed most of it, leaving -$6.3M in free cash flow. This results in a low score of 7/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Arcutis Biotherapeutics, Inc. generates a -8.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 22/100. This is up from -88.9% the prior year.

Altman Z-Score Safe

6.31

Arcutis Biotherapeutics, Inc. scores 6.31, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.4B) relative to total liabilities ($243.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

4/9

Arcutis Biotherapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.35x

For every $1 of reported earnings, Arcutis Biotherapeutics, Inc. generates $0.35 in operating cash flow (-$5.6M OCF vs -$16.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1.0x

Arcutis Biotherapeutics, Inc. earns $-1.0 in operating income for every $1 of interest expense (-$12.2M vs $12.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$376.1M

YoY+91.3%

Arcutis Biotherapeutics, Inc. generated $376.1M in revenue in fiscal year 2025. This represents an increase of 91.3% from the prior year.

EBITDA

-$6.9M

YoY+94.5%

Arcutis Biotherapeutics, Inc.'s EBITDA was -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 94.5% from the prior year.

Net Income

-$16.1M

YoY+88.5%

Arcutis Biotherapeutics, Inc. reported -$16.1M in net income in fiscal year 2025. This represents an increase of 88.5% from the prior year.

EPS (Diluted)

$-0.13

YoY+88.8%

Arcutis Biotherapeutics, Inc. earned $-0.13 per diluted share (EPS) in fiscal year 2025. This represents an increase of 88.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$6.3M

YoY+94.4%

Arcutis Biotherapeutics, Inc. generated -$6.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 94.4% from the prior year.

Cash & Debt

$42.9M

YoY-39.9%

5Y CAGR-8.0%

Arcutis Biotherapeutics, Inc. held $42.9M in cash against $108.0M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

123M

YoY+4.7%

5Y CAGR+19.7%

Arcutis Biotherapeutics, Inc. had 123M shares outstanding in fiscal year 2025. This represents an increase of 4.7% from the prior year.

Margins & Returns

Gross Margin

90.2%

YoY-0.0pp

Arcutis Biotherapeutics, Inc.'s gross margin was 90.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.0 percentage points from the prior year.

Operating Margin

-3.3%

YoY+62.1pp

Arcutis Biotherapeutics, Inc.'s operating margin was -3.3% in fiscal year 2025, reflecting core business profitability. This is up 62.1 percentage points from the prior year.

Net Margin

-4.3%

YoY+67.0pp

Arcutis Biotherapeutics, Inc.'s net profit margin was -4.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 67.0 percentage points from the prior year.

Return on Equity

-8.5%

YoY+80.4pp

5Y CAGR+41.6pp

Arcutis Biotherapeutics, Inc.'s ROE was -8.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 80.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$77.1M

YoY+0.8%

5Y CAGR-7.7%

Arcutis Biotherapeutics, Inc. invested $77.1M in research and development in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$686K

YoY+379.7%

5Y CAGR+16.4%

Arcutis Biotherapeutics, Inc. invested $686K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 379.7% from the prior year.

ARQT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$376.1M+91.3%	$196.5M+229.7%	$59.6M+1517.1%	$3.7M	$0	$0
Cost of Revenue	$36.7M+91.8%	$19.1M+283.6%	$5.0M+561.4%	$754K	$0	N/A
Gross Profit	$339.4M+91.3%	$177.4M+224.8%	$54.6M+1762.9%	$2.9M	$0	N/A
R&D Expenses	$77.1M+0.8%	$76.4M-30.9%	$110.6M-39.4%	$182.4M+25.3%	$145.6M+26.2%	$115.3M
SG&A Expenses	$274.6M+19.7%	$229.4M+23.9%	$185.1M+51.6%	$122.1M+100.3%	$61.0M+185.8%	$21.3M
Operating Income	-$12.2M+90.5%	-$128.4M+46.7%	-$241.1M+20.1%	-$301.6M-46.0%	-$206.5M-51.1%	-$136.6M
Interest Expense	$12.1M-55.5%	$27.2M-8.6%	$29.7M+89.8%	$15.7M	$0	$0
Income Tax	$1.2M+81.0%	$647K-79.2%	$3.1M	$0	$0	$0
Net Income	-$16.1M+88.5%	-$140.0M+46.6%	-$262.1M+15.8%	-$311.5M-50.9%	-$206.4M-52.1%	-$135.7M
EPS (Diluted)	$-0.13+88.8%	$-1.16+69.3%	$-3.78+33.2%	$-5.66-35.4%	$-4.18-10.0%	$-3.80

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$105.4M-18.6%	$129.5M+30.5%	$99.2M+21.7%	$81.5M+23.8%	$65.8M-7.7%	$71.4M+59.4%	$44.8M+45.0%	$30.9M
Cost of Revenue	$9.8M-16.3%	$11.7M+34.6%	$8.7M+15.9%	$7.5M-15.2%	$8.8M+27.9%	$6.9M+25.5%	$5.5M+58.9%	$3.5M
Gross Profit	$95.6M-18.8%	$117.8M+30.1%	$90.5M+22.3%	$74.0M+29.8%	$57.0M-11.5%	$64.5M+64.2%	$39.3M+43.3%	$27.4M
R&D Expenses	$30.6M+49.8%	$20.5M+4.3%	$19.6M+0.8%	$19.5M+10.9%	$17.5M+21.2%	$14.5M-25.7%	$19.5M+1.1%	$19.3M
SG&A Expenses	$74.1M-6.2%	$79.0M+26.6%	$62.4M-9.8%	$69.2M+8.1%	$64.0M+11.1%	$57.6M-2.1%	$58.8M+1.1%	$58.2M
Operating Income	-$9.1M-149.4%	$18.4M+115.7%	$8.5M+158.4%	-$14.6M+40.4%	-$24.5M-221.4%	-$7.6M+80.5%	-$39.1M+22.0%	-$50.1M
Interest Expense	$4.4M+45.6%	$3.0M-2.3%	$3.1M+1.4%	$3.0M+1.6%	$3.0M-46.3%	$5.6M-16.6%	$6.7M-11.1%	$7.5M
Income Tax	$93K-80.2%	$470K+487.5%	$80K-76.6%	$342K+22.6%	$279K-13.6%	$323K	$0	$0
Net Income	-$11.3M-164.9%	$17.4M+134.8%	$7.4M+146.6%	-$15.9M+36.6%	-$25.1M-132.3%	-$10.8M+74.0%	-$41.5M+20.6%	-$52.3M
EPS (Diluted)	$-0.09	N/A	$0.06+146.2%	$-0.13+35.0%	$-0.20	N/A	$-0.33+21.4%	$-0.42

ARQT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$433.0M+24.1%	$348.9M+2.2%	$341.4M-24.0%	$449.3M+10.1%	$408.2M+36.8%	$298.3M
Current Assets	$411.2M+22.5%	$335.8M+1.6%	$330.4M-24.5%	$437.4M+8.6%	$402.8M+37.5%	$292.8M
Cash & Equivalents	$42.9M-39.9%	$71.3M-19.3%	$88.4M+64.8%	$53.6M-44.4%	$96.4M+48.2%	$65.1M
Inventory	$22.6M+55.8%	$14.5M+10.6%	$13.1M+74.8%	$7.5M	$0	N/A
Accounts Receivable	$146.2M+100.1%	$73.1M+183.1%	$25.8M+205.1%	$8.5M	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$243.5M+27.3%	$191.3M-24.3%	$252.7M+5.4%	$239.7M+117.0%	$110.5M+299.6%	$27.6M
Current Liabilities	$129.8M+60.3%	$81.0M+73.6%	$46.7M+23.4%	$37.8M+13.4%	$33.3M+47.4%	$22.6M
Long-Term Debt	$108.0M+0.7%	$107.2M-46.9%	$201.8M+2.0%	$197.8M+173.4%	$72.3M	$0
Total Equity	$189.5M+20.3%	$157.5M+77.7%	$88.7M-57.7%	$209.6M-29.6%	$297.7M+10.0%	$270.6M
Retained Earnings	-$1.1B-1.4%	-$1.1B-14.3%	-$981.9M-36.4%	-$719.8M-76.3%	-$408.3M-102.2%	-$201.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$460.0M+6.2%	$433.0M+16.7%	$371.0M+5.3%	$352.4M+2.4%	$344.1M-1.4%	$348.9M-20.2%	$437.4M-1.7%	$444.8M
Current Assets	$438.1M+6.5%	$411.2M+17.8%	$349.2M+4.9%	$332.8M+2.8%	$323.7M-3.6%	$335.8M-20.7%	$423.7M-2.5%	$434.6M
Cash & Equivalents	$34.8M-19.0%	$42.9M-8.9%	$47.1M-35.2%	$72.7M+37.0%	$53.1M-25.6%	$71.3M-47.1%	$134.9M+60.0%	$84.3M
Inventory	$37.4M+65.2%	$22.6M+1.0%	$22.4M+37.3%	$16.3M-1.7%	$16.6M+14.4%	$14.5M+3.6%	$14.0M+1.0%	$13.9M
Accounts Receivable	$144.4M-1.3%	$146.2M+27.0%	$115.1M+7.9%	$106.7M+24.9%	$85.4M+16.9%	$73.1M+21.5%	$60.1M+38.5%	$43.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$270.4M+11.0%	$243.5M+14.4%	$212.9M-0.3%	$213.5M+6.0%	$201.4M+5.3%	$191.3M-31.8%	$280.7M+8.7%	$258.3M
Current Liabilities	$163.2M+25.7%	$129.8M+30.1%	$99.8M-4.0%	$103.9M+14.1%	$91.1M+12.5%	$81.0M-53.0%	$172.4M+235.8%	$51.4M
Long-Term Debt	$101.5M-6.0%	$108.0M+0.4%	$107.5M+0.4%	$107.0M-0.5%	$107.6M+0.4%	$107.2M+2.0%	$105.1M-48.4%	$203.8M
Total Equity	$189.6M+0.1%	$189.5M+19.9%	$158.1M+13.7%	$139.0M-2.6%	$142.7M-9.4%	$157.5M+0.6%	$156.6M-16.0%	$186.4M
Retained Earnings	-$1.1B-1.0%	-$1.1B+1.5%	-$1.2B+0.6%	-$1.2B-1.4%	-$1.1B-2.2%	-$1.1B-1.0%	-$1.1B-3.9%	-$1.1B

ARQT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.6M+95.0%	-$112.2M+54.6%	-$247.1M+4.1%	-$257.7M-47.6%	-$174.6M-54.5%	-$113.0M
Capital Expenditures	$686K+379.7%	$143K-66.6%	$428K+28.5%	$333K-66.5%	$995K+210.0%	$321K
Free Cash Flow	-$6.3M+94.4%	-$112.3M+54.6%	-$247.5M+4.1%	-$258.0M-46.9%	-$175.6M-54.9%	-$113.4M
Investing Cash Flow	-$30.3M-205.0%	$28.8M-84.0%	$180.2M+306.7%	-$87.2M-14.8%	-$76.0M+58.2%	-$181.8M
Financing Cash Flow	$7.0M-89.5%	$66.2M-34.7%	$101.3M-66.4%	$301.8M+7.0%	$281.9M-5.4%	$298.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$2.2M-91.4%	$26.2M+1592.9%	-$1.8M-641.4%	$324K+101.1%	-$30.4M-3961.5%	-$748K+97.8%	-$34.7M+23.1%	-$45.1M
Capital Expenditures	$0	$0	$0-100.0%	$78K-87.2%	$608K	$0-100.0%	$143K	$0
Free Cash Flow	$2.2M-91.4%	$26.2M+1592.9%	-$1.8M-813.0%	$246K+100.8%	-$31.0M-4042.8%	-$748K+97.9%	-$34.8M+22.8%	-$45.1M
Investing Cash Flow	-$11.3M+66.8%	-$34.2M-35.4%	-$25.2M-244.9%	$17.4M+48.3%	$11.8M-66.3%	$34.9M-58.9%	$84.8M+236.4%	-$62.1M
Financing Cash Flow	$1.1M-71.3%	$3.7M+152.2%	$1.5M+7.0%	$1.4M+249.4%	$395K+100.4%	-$97.4M-24823.6%	$394K-72.9%	$1.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ARQT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	90.2%-0.0pp	90.3%-1.4pp	91.6%+12.1pp	79.5%	N/A	N/A
Operating Margin	-3.3%+62.1pp	-65.3%+339.2pp	-404.5%+7778.6pp	-8183.0%	N/A	N/A
Net Margin	-4.3%+67.0pp	-71.3%+368.5pp	-439.8%+8010.0pp	-8449.8%	N/A	N/A
Return on Equity	-8.5%+80.4pp	-88.9%+206.8pp	-295.7%-147.0pp	-148.6%-79.3pp	-69.3%-19.2pp	-50.1%
Return on Assets	-3.7%+36.4pp	-40.1%+36.7pp	-76.8%-7.5pp	-69.3%-18.8pp	-50.6%-5.1pp	-45.5%
Current Ratio	3.17-1.0	4.15-2.9	7.08-4.5	11.57-0.5	12.09-0.9	12.96
Debt-to-Equity	0.57-0.1	0.68-1.6	2.28+1.3	0.94+0.7	0.24+0.2	0.00
FCF Margin	-1.7%+55.5pp	-57.1%+358.1pp	-415.2%+6585.6pp	-7000.8%	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	90.7%-0.2pp	91.0%-0.3pp	91.3%+0.4pp	90.8%+4.2pp	86.6%-3.7pp	90.3%+2.6pp	87.7%-1.1pp	88.8%
Operating Margin	-8.6%-22.8pp	14.2%+5.6pp	8.6%+26.5pp	-17.9%+19.3pp	-37.3%-26.6pp	-10.7%+76.6pp	-87.3%+75.0pp	-162.3%
Net Margin	-10.7%-24.1pp	13.4%+6.0pp	7.5%+27.0pp	-19.5%+18.6pp	-38.1%-22.9pp	-15.1%+77.7pp	-92.8%+76.8pp	-169.6%
Return on Equity	-6.0%-15.1pp	9.2%+4.5pp	4.7%+16.1pp	-11.4%+6.1pp	-17.6%-10.7pp	-6.8%+19.7pp	-26.5%+1.6pp	-28.1%
Return on Assets	-2.5%-6.5pp	4.0%+2.0pp	2.0%+6.5pp	-4.5%+2.8pp	-7.3%-4.2pp	-3.1%+6.4pp	-9.5%+2.3pp	-11.8%
Current Ratio	2.68-0.5	3.17-0.3	3.50+0.3	3.20-0.4	3.55-0.6	4.15+1.7	2.46-6.0	8.46
Debt-to-Equity	0.54-0.0	0.57-0.1	0.68-0.1	0.77+0.0	0.75+0.1	0.680.0	0.67-0.4	1.09
FCF Margin	2.1%-18.1pp	20.2%+22.0pp	-1.8%-2.1pp	0.3%+47.4pp	-47.1%-46.0pp	-1.1%+76.8pp	-77.8%+68.4pp	-146.2%

Similar Companies

Apogee Therapeutics Inc APGE

$10.2B

Tarsus Pharmaceuticals, Inc. TARS

$2.6B

Travere Therapeutics Inc TVTX

$5.3B

Agios Pharmaceuticals Inc AGIO

$2.2B

Disc Medicine Inc IRON

$2.8B

Frequently Asked Questions

What is Arcutis Biotherapeutics, Inc.'s annual revenue?

Arcutis Biotherapeutics, Inc. (ARQT) reported $376.1M in total revenue for fiscal year 2025. This represents a 91.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Arcutis Biotherapeutics, Inc.'s revenue growing?

Arcutis Biotherapeutics, Inc. (ARQT) revenue grew by 91.3% year-over-year, from $196.5M to $376.1M in fiscal year 2025.

Is Arcutis Biotherapeutics, Inc. profitable?

No, Arcutis Biotherapeutics, Inc. (ARQT) reported a net income of -$16.1M in fiscal year 2025, with a net profit margin of -4.3%.

What is Arcutis Biotherapeutics, Inc.'s EBITDA?

Arcutis Biotherapeutics, Inc. (ARQT) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Arcutis Biotherapeutics, Inc. have?

As of fiscal year 2025, Arcutis Biotherapeutics, Inc. (ARQT) had $42.9M in cash and equivalents against $108.0M in long-term debt.

What is Arcutis Biotherapeutics, Inc.'s gross margin?

Arcutis Biotherapeutics, Inc. (ARQT) had a gross margin of 90.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Arcutis Biotherapeutics, Inc.'s operating margin?

Arcutis Biotherapeutics, Inc. (ARQT) had an operating margin of -3.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Arcutis Biotherapeutics, Inc.'s net profit margin?

Arcutis Biotherapeutics, Inc. (ARQT) had a net profit margin of -4.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Arcutis Biotherapeutics, Inc.'s return on equity (ROE)?

Arcutis Biotherapeutics, Inc. (ARQT) has a return on equity of -8.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Arcutis Biotherapeutics, Inc.'s free cash flow?

Arcutis Biotherapeutics, Inc. (ARQT) generated -$6.3M in free cash flow during fiscal year 2025. This represents a 94.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Arcutis Biotherapeutics, Inc.'s operating cash flow?

Arcutis Biotherapeutics, Inc. (ARQT) generated -$5.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Arcutis Biotherapeutics, Inc.'s total assets?

Arcutis Biotherapeutics, Inc. (ARQT) had $433.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Arcutis Biotherapeutics, Inc.'s capital expenditures?

Arcutis Biotherapeutics, Inc. (ARQT) invested $686K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Arcutis Biotherapeutics, Inc. spend on research and development?

Arcutis Biotherapeutics, Inc. (ARQT) invested $77.1M in research and development during fiscal year 2025.

How many shares does Arcutis Biotherapeutics, Inc. have outstanding?

Arcutis Biotherapeutics, Inc. (ARQT) had 123M shares outstanding as of fiscal year 2025.

What is Arcutis Biotherapeutics, Inc.'s current ratio?

Arcutis Biotherapeutics, Inc. (ARQT) had a current ratio of 3.17 as of fiscal year 2025, which is generally considered healthy.

What is Arcutis Biotherapeutics, Inc.'s debt-to-equity ratio?

Arcutis Biotherapeutics, Inc. (ARQT) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Arcutis Biotherapeutics, Inc.'s return on assets (ROA)?

Arcutis Biotherapeutics, Inc. (ARQT) had a return on assets of -3.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Arcutis Biotherapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Arcutis Biotherapeutics, Inc. (ARQT) had $42.9M in cash against an annual operating cash burn of $5.6M. This gives an estimated cash runway of approximately 92 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Arcutis Biotherapeutics, Inc.'s Altman Z-Score?

Arcutis Biotherapeutics, Inc. (ARQT) has an Altman Z-Score of 6.31, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Arcutis Biotherapeutics, Inc.'s Piotroski F-Score?

Arcutis Biotherapeutics, Inc. (ARQT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Arcutis Biotherapeutics, Inc.'s earnings high quality?

Arcutis Biotherapeutics, Inc. (ARQT) has an earnings quality ratio of 0.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Arcutis Biotherapeutics, Inc. cover its interest payments?

Arcutis Biotherapeutics, Inc. (ARQT) has an interest coverage ratio of -1.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Arcutis Biotherapeutics, Inc.?

Arcutis Biotherapeutics, Inc. (ARQT) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.